To cosmetics industry stakeholders, the EU’s talk of instituting a generic risk management approach to eliminate “most hazardous” chemicals spells wholesale adoption of the precautionary principle, the disposal of exposure and risk considerations, and, ultimately, increased cosmetic ingredient restrictions and bans without proportionate human health benefits.
Industry stakeholders weighing in on the EU’s planned revision of the Cosmetic Products Regulation share a common concern, that the EU is on the brink of scuttling risk assessment in the cosmetics sector in favor of a “modern” system that restricts and bans ingredients based on hazard signals alone.
In 29 October feedback to the Commission, trade association Cosmetics Europe states, “Any revision of the CPR should acknowledge...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
